NTLA Earnings

Quarterly EPS
$-1.34
Q3 2024
$-1.26
Q4 2024
$-1.10
Q1 2025
$-0.98
Q2 2025
$-0.92
Q3 2025
$-0.83
Q4 2025
$-0.81
Q1 2026
$-0.80
Q2 2026
Latest Revenue7.7M
Latest Net Income-106634000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.807.7M-106634000-46.2%+18.4%
Q1 2026-$0.8115.0M-96231000-9.5%+26.4%
Q4 2025-$0.8323.0M-95786000+78.8%+34.1%
Q3 2025-$0.9213.8M-101324000+51.3%+31.3%
Q2 2025-$0.9814.2M-101255000+104.8%+35.5%
Q1 2025-$1.1016.6M-114329000-42.5%+1.8%
Q4 2024-$1.2612.9M-128898000
Q3 2024-$1.349.1M-135712000-24.0%+2.9%
Q2 2024-$1.527.0M-146975000
Q1 2024-$1.1228.9M-107436000
Q4 2023
Q3 2023-$1.3812.0M-122224000
Intellia Therapeutics (NTLA) — Earnings